These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26565663)

  • 1. Effects of hepatitis B surface antigen (HBsAg) positivity of donors in HBsAg(+) renal transplant recipients: comparison of outcomes with HBsAg(+) and HBsAg(-) donors.
    Yilmaz VT; Aliosmanoglu I; Erbis H; Ulger BV; Cetinkaya R; Suleymanlar G; Kocak H
    Transpl Infect Dis; 2016 Feb; 18(1):55-62. PubMed ID: 26565663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of prophylactic and therapeutic lamivudine treatments in hepatitis B surface antigen-positive renal allograft recipients.
    Yang YW; Lee CY; Hu RH; Lee PH; Tsai MK
    Clin Exp Nephrol; 2014 Feb; 18(1):144-50. PubMed ID: 23605388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The outcomes of kidney transplantation in hepatitis B surface antigen (HBsAg)-negative recipients receiving graft from HBsAg-positive donors: a retrospective, propensity score-matched study.
    Chancharoenthana W; Townamchai N; Pongpirul K; Kittiskulnam P; Leelahavanichkul A; Avihingsanon Y; Suankratay C; Wattanatorn S; Kittikowit W; Praditpornsilpa K; Tungsanga K; Eiam-Ong S
    Am J Transplant; 2014 Dec; 14(12):2814-20. PubMed ID: 25395260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of prophylactic versus preemptive lamivudine treatment and tenofovir on HBsAg+ kidney transplant recipients.
    Ruhi Ç; Süleymanlar İ; Koçak H; Dinçkan A; Ersoy F; Süleymanlar G
    Exp Clin Transplant; 2015 Feb; 13(1):35-40. PubMed ID: 25019317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-transplant donor HBV DNA+ and male recipient are independent risk factors for treatment failure in HBsAg+ donors to HBsAg- kidney transplant recipients.
    Wang XD; Feng SJ; Liu JP; Song TR; Huang ZL; Fan Y; Shi YY; Chen LY; Lv YH; Xu ZL; Li XH; Wang L; Lin T
    BMC Infect Dis; 2021 Jan; 21(1):41. PubMed ID: 33422017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
    Chan TM; Fang GX; Tang CS; Cheng IK; Lai KN; Ho SK
    Hepatology; 2002 Nov; 36(5):1246-52. PubMed ID: 12395336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
    Choudhary NS; Saraf N; Saigal S; Mohanka R; Rastogi A; Goja S; Menon PB; Soin AS
    Transpl Infect Dis; 2015 Jun; 17(3):329-33. PubMed ID: 25682715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cadaveric renal transplantation in hepatitis B antigen-positive recipients using hepatitis B antigen-positive donor organs with lamivudine treatment.
    Kim JA; Huh W; Lee KW; Kim SJ; Kim YG; Kim DJ; Joh JW; Oh HY
    Transplant Proc; 2004 Jun; 36(5):1434-7. PubMed ID: 15251352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen.
    Ahn HJ; Kim MS; Kim YS; Kim SI; Huh KH; Ju MK; Ahn SH; Han KH
    J Med Virol; 2007 Nov; 79(11):1655-63. PubMed ID: 17854044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation.
    Yu S; Yu J; Zhang W; Cheng L; Ye Y; Geng L; Yu Z; Yan S; Wu L; Wang W; Zheng S
    J Hepatol; 2014 Oct; 61(4):809-15. PubMed ID: 24824283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of hepatitis B core antibody positive grafts in living donor liver transplantation.
    Udayakumar VP; Surendran S; Padma UD
    Indian J Gastroenterol; 2018 Jan; 37(1):39-43. PubMed ID: 29450703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments.
    Yap DY; Tang CS; Yung S; Choy BY; Yuen MF; Chan TM
    Transplantation; 2010 Aug; 90(3):325-30. PubMed ID: 20562676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
    Wadhawan M; Gupta S; Goyal N; Taneja S; Kumar A
    Liver Transpl; 2013 Sep; 19(9):1030-5. PubMed ID: 23788470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
    Vizzini G; Gruttadauria S; Volpes R; D'Antoni A; Pietrosi G; Filì D; Petridis I; Pagano D; Tuzzolino F; Santonocito MM; Gridelli B
    Clin Transplant; 2011; 25(1):E77-81. PubMed ID: 21039887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Long-Term Outcomes in Hbs Ag-Negative Renal Transplant Recipients Transplanted from Hbs Ag-Positive Donors.
    Yilmaz VT; Ulger BV; Aliosmanoglu İ; Erbis H; Tuna Y; Akbas H; Ozdem S; Cetinkaya R; Suleymanlar G; Kocak H
    Ann Transplant; 2015 Jul; 20():390-6. PubMed ID: 26156252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of viral hepatitis in solid organ transplantation].
    Mikolašević I; Sladoje-Martinović B; Orlić L; Milić S; Lukenda V; Župan Ž; Štimac D; Rački S
    Acta Med Croatica; 2014 Apr; 68(2):151-9. PubMed ID: 26012153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of kidney donors with hepatitis B, hepatitis C, or brain tumor: a single-center experience.
    Tatar E; Turan MN; Firat O; Sezer TO; Sozbilen M; Solak I; Toz H; Hoscoskun C
    Transplant Proc; 2012; 44(6):1601-3. PubMed ID: 22841224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Hepatitis B Virus on Graft and Overall Survival in Kidney Transplant Patients.
    Harmancı Ö; İlin S; Öcal S; Korkmaz M; Moray G; Çolak T; Selçuk H; Özdemir BH; Haberal M
    Exp Clin Transplant; 2015 Nov; 13 Suppl 3():36-40. PubMed ID: 26640908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.